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A B S T R A C T   
Myocardial infarction is caused by an interruption of coronary blood flow, leading to one of the main death 
causes worldwide. Current therapeutic approaches are palliative and not able to solve the loss of cardiac tissue. 
Cardiosphere derived cells (CDCs) reduce scarring, and increase viable myocardium, with safety and adequate 
biodistribution, but show a low rate engraftment and survival after implantation. In order to solve the low 
retention, we propose the encapsulation of CDCs within three-dimensional alginate-poly-L-lysine-alginate matrix 
as therapy for cardiac regeneration. In this work, we demonstrate the encapsulation of CDCs in alginate matrix, 
with no decrease in viability over a month, and showing the preservation of CDCs phenotype, differentiation 
potential, gene expression profile and growth factor release after encapsulation, moving a step forward to clinical 
translation of CDCs therapy in regeneration in heart failure.   
1. Introduction 
More than 23 million people suffer from heart failure worldwide, 
leading to 32% deaths (Bui et al., 2011, Nichols et al., 2014). Myocardial 
infarction (MI) is an ischemic heart disease caused by deterioration and 
obstruction of the arteries of the heart (coronary arteriosclerosis). The 
accumulation of cholesterol plaques, lipids (fats) and inflammatory cells 
in the walls of these arteries, leads to the interruption of vascular flow to 
the heart muscle. After an acute MI, cardiac cells in the affected area die 
due to the lack of blood supply. The heart has limited capacity for self- 
renewal and, its regeneration potential by itself is unable to counteract 
the loss of heart tissue during MI. 
Despite advances in cardiovascular biology and medical therapy over 
the last 30 years, the prognosis of patients hospitalized with heart failure 
remains poor, with a 5-year mortality that approaches 50% (Roger et al., 
2011). Cardiac transplantation is the standard therapy to replace the 
injured heart, but donor supply is not sufficient to cover the demand of 
heart transplants (Lund et al., 2013). Moreover, this therapy is very 
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invasive and requires treatment with immunosuppressants for life. An 
alternative for this treatment is the development of regenerative thera-
peutic strategies to reverse the progression of advanced heart failure, 
focusing on the regeneration of the affected cells. In this regard, trans-
planted mesenchymal stem cells (MSCs) are able to engraft and differ-
entiate into vascular cells and cardiomyocytes, secreting paracrine 
factors and recruiting endogenous cardiac stem cells (Williams and 
Hare, 2011, Sheng et al., 2013, Chiu, 2003). Intramyocardial injection of 
MSCs, therefore, is being investigated as a therapeutic option in the 
treatment of chronic myocardial ischemia (Van Ramshorst et al., 2011, 
Van Ramshorst et al., 2009, Mathiasen et al., 2015, Mathur et al., 2020). 
Thus, hypoxic MSCs conditioned culture medium shows to reduce 
apoptosis and necrosis of isolated rat cardiomyocytes exposed to low 
oxygen in-vivo (Gnecchi et al., 2005), reappearance of myocardial tissue 
and restoration of contractility is detected after MSC implantation 
(Amado et al., 2006). 
Cardiosphere derived cells (CDCs) have also emerged as an effective 
cell type for cardiovascular cell therapy. CDCs are obtained from cardiac 
tissue explants of euthanized large white pig from endomyocardial bi-
opsy (Blázquez et al., 2016, Makkar et al., 2012, Smith et al., 2007). 
These cells are clonogenic, multipotent stem cells that secrete growth 
factors able to promote revascularization and support cardiac recovery 
after MI. For example, CDCs secrete insulin-like growth factor 1 (IGF-1), 
whose administration leads to the activation of cardiac stem cells, 
increasing cardiomyogenesis, and significantly improving cardiac 
function (Ellison et al., 2011, Báez-Díaz et al., 2020). Moreover, they 
release vascular endothelial growth factor (VEGF), a specific mitogen for 
vascular endothelial cells, whose expression is potentiated in response to 
hypoxia, inducing endothelial cell proliferation, promoting cell migra-
tion and inhibiting apoptosis (NEUFELD et al., 1999). CDCs also release 
macrophage stimulating protein (MSP) with a fundamental role inhib-
iting apoptosis during regeneration of endothelial cells and car-
diomyocytes potential after myocardial infarction (Frangogiannis, 2015, 
Cantaluppi et al., 2008). Finally, they also secrete transforming growth 
factor beta 1 (TGF-ß1) cytokine contributing in the regulation of 
inflammation, extracellular matrix deposition, cell proliferation, dif-
ferentiation and growth. TGF-ß1 causes the transformation of cardiac 
fibroblasts to myofibroblasts, helping in the regeneration after 
myocardial infarction when fibrotic tissues are formed to replace the 
area lost following cardiomyocytes necrosis (Tarbit et al., 2019, Shi 
et al., 2011). The joint action of released factors by CDCs plays a central 
role in vasculogenesis regulation, inducing angiogenesis and per-
meabilization of blood vessels and achieving myocardial regeneration, 
features that can prevent and reverse remodel the ischemically injured 
ventricle. 
CDCs can be safely delivered via the intracoronary route after 
myocardial infarction reducing scarring, increasing viable myocardium, 
and boosting cardiac function in preclinical and clinical models (Makkar 
et al., 2012). Although intrapericardially administration of CDCs has 
shown safety and adequate biodistribution (Blázquez et al., 2016), the 
low engraftment rate and survival of transplanted CDCs following im-
plantation remains a major challenge. The constant heart contraction, 
contributing to mechanical lost by squeezing injected cells out the 
myocardium, has led to low retention of transplanted cells in current 
preclinical studies, independently of the delivery method (Fukushima 
et al., 2013, Van Ramshorst et al., 2011). Cell alginate microencapsu-
lation represents an alternative strategy to increase retention, thanks to 
a higher adherence of microcapsules that could circumvent the wash out 
into the bloodstream caused by the contractile heart forces (Paul et al., 
2009). 
Microencapsulation of cells allows their transplantation in absence of 
immunosuppression along a wide variety of diseases, with long reten-
tion in the engrafted tissue (Safley et al., 2008). In cell microencapsu-
lation, immobilized foreign cells within a spherical polymeric matrix are 
protected from the host immune system by an artificial membrane, 
allowing nutrients to diffuse inside the capsule while releasing 
therapeutic products and waste outside (de Vos et al., 2006, Orive et al., 
2010, Ciriza et al., 2015, Pérez-Luna and González-Reynoso, 2018). 
Microcapsules are three-dimensional hydrogels that can be delivered 
into the body via minimally invasive administration with good 
biocompatibility (El-Sherbiny and Yacoub, 2013, Lee and Kim, 2018). 
Alginate, a natural polymer isolated from brown algae (Phaeophyceae) 
that can form hydrogels in the presence of calcium ions with good 
biocompatibility and low toxicity (Lee and Mooney, 2012, Park et al., 
2017), is a common biomaterial used in microencapsulation. Coating 
alginate microcapsules with poly-L-lysine (PLL) increase their stiffness, 
while a second coating with alginate, obtaining alginate-poly-L-lysine- 
alginate (APA) microcapsules, reduces immunological reaction after 
implantation. 
We hypothesize that the administration of encapsulated CDCs will 
increase retention in the heart tissue after implantation, promoting the 
local and continuous release of biomolecules and growth factors, 
therefore promoting cardiac repair. However, microencapsulation can 
modify the nature of CDCs. In this paper, we demonstrate that cell 
encapsulation does not alter CDCs features, keeping a long viability and 
growth factor release, and providing a step forward to clinical trans-
lation of CDCs therapy in the regeneration of myocardial infarction. 
2. Material and methods 
2.1. Materials 
Poly-L-lysine and calcium chloride (CaCl2) were purchased from 
Sigma Aldrich (Madrid, Spain). Ultrapure low viscosity and high 
guluronic (UPLVG) alginate were purchased from NovaMatrix (FMC 
Biopolymer, Norway). Roswell Park, Dulbecco’s Modified Eagle’s Me-
dium (DMEM) Ham’s F12 with UltraGlutamina 3.996 mM, Iscove’s 
Modified Dulbecco’s Medium (IMDM), fetal bovine serum and pen-
icillin–streptomycin solution were purchased from Lonza (Switzerland), 
phosphate-buffered saline (PBS), Dulbecco’s phosphate-buffered saline 
(DPBS), trypsin-EDTA (0.25%), and LIVE/DEAD kit were purchased 
from Life Technologies (Invitrogen S.A., Spain). The ELISA Kits MST-1, 
TGF-ß1, IGF-1, and VEGF, were purchased from Elabscience, R&D Sys-
tems Inc., LifeSpain BioScience, Inc. and My BioSource, Inc. 
respectively. 
2.2. Cell culture 
CDCs were obtained from cardiac tissue explants of euthanized pigs. 
Tissues were subjected to three successive enzymatic digestions, 
culturing explants with complete explant medium composed by 2 mM L- 
glutamine (Lonza), 1% penicillin–streptomycin (Lonza), 0.2 mM 2-mer-
captoethanol (Sigma), and 10% Fetal Bovine Serum (FBS) in IMDM 
(HyClone) at 37 ◦C and 5% CO2. Three weeks after culture, fibroblast- 
like cells migrating from tissue explants were seeded. Suspended cells 
clusters, called cardiospheres, were formed, and cells migrating from 
those cardiospheres, called CDCs, were selected. CDCs were seeded 
again and expanded with complete explant medium at 37 ◦C and 5% 
CO2. CDCs expanded as a monolayer cell culture were observed under 
optical microscopy. 
Cardiosphere-derived cells were cultured in complete medium con-
sisting of 65% DMEM Ham’s F12 with UltraGlutamina a 3.996 mM and 
35% IMDM supplemented with 10% of FBS, 1% Penicillin-Streptomycin, 
2 mM L-glutamine (Invitrogen), and 0.1 mM 2-mercaptoethanol (Sigma 
Aldrich, United States). Cells were maintained at 37 ◦C in humidified 5% 
CO2 atmosphere, and passaged every 2–3 days. 
2.3. Cell encapsulation 
UPLVG alginate was resuspended in 1% mannitol to obtain 1.5% (w/ 
v) alginate and 0.1% alginate (FMC Biopolymer, Norway). Final solu-
tions were filtered through a 0.22 µm syringe filter (Millipore, MA, 
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USA). Next, cardiosphere-derived cells were suspended at 5 × 106 cells/ 
mL in alginate 1.5% solution and extruded with an electrostatic atomi-
zation generator (Nisco, Switzerland) and a peristaltic pump (flow rate: 
5.9 mL/h). The resulting microcapsules were completely gelled by 
agitation for 15 min in a 55 mM CaCl2 solution. Next, microcapsules 
were ionically linked with 0.05% (w/v) PLL by agitation for 5 min, 
followed by a second coating with 0.1% alginate for another 5 min. All 
the procedures were performed at room temperature, under aseptic 
conditions, and maintained with complete medium at 37 ◦C, in a hu-
midified 5% CO2 and 95% air atmosphere standard incubator. Micro-
capsules morphology and diameter were examined under an inverted 
optical microscopy (Nikon TSM, Japan). 
2.4. Cell viability 
Encapsulated CDCs viability was assessed by microscopy imaging 
after calcein ethidium staining. Briefly, 50 μL of microcapsules were 
rinsed twice in DPBS (Gibco, United States), next resuspended in 500 μL 
of 0.5 μM calcein AM (Life Technologies, United States) and 0.5 μM 
ethidium homodimer-1 (Life Technologies, United States). The samples 
were incubated in 24-well-plates for 45 min at room temperature, pro-
tecting from light. Samples were observed under a Nikon Eclipse 
TE2000-S confocal microscope with 470 nm wavelength for calcein AM 
and 575 nm wavelength for ethidium homodimer staining. Random 
images were analyzed with the NIS Elements AR software, version 
4.51.00. At least three independent experiments were performed for 
each condition. 
2.5. Metabolic activity 
Metabolic activity was determined at day 1, 7, 21 and 42 of culture 
by Cell Counting Kit-8, CCK-8 (SigmaAldrich, United States), following 
the manufacturer recommendations. Briefly, 25 μL of microcapsules and 
1.25 × 105 of non-encapsulated cells were rinsed, resuspended into 500 
μL of culture medium supplemented with 50 μL of CCK-8 reagent, and 
plated in 5 wells of a 96-well plate. After incubation for 4 h at 37 ◦C, 
absorbance was read out on an Infinite M200 TECAN plate reader 
(TECAN Trading AG, Switzerland) at 450 nm and corrected at 650 nm. 
2.6. Phenotypic analysis of non– encapsulated and encapsulated CDCs by 
flow cytometry 
Non-encapsulated CDCs were detached from culture flasks with 
0.25% trypsin solution, washed twice with PBS and suspended in culture 
medium. Encapsulated CDCs were previously incubated with 1 mg/mL 
alginate lyase (SigmaAldrich, United States) for 30 min at 37 ◦C. After 
washing twice with DPBS, the lysates were spun down and rinsed twice 
with DPBS. Cells extracted from microcapsules were treated following 
the same procedure than non-encapsulated CDCs. All samples were 
stained with FITC -conjugated porcine monoclonal antibodies against 
Mouse anti Pig CD31: FITC (LCI-4), Rat anti Pig wCD44: FITC 
(MAC329), Mouse anti Pig CD45: FITC (K252.1E4), Mouse anti Pig 
CD61: FITC (JM2E5), Mouse anti Pig SLA Class I: FITC (JM1E3) and 
Mouse anti Pig SLA Class II DR: FITC (2E9/13) purchased in Bio-Rad 
(United States), Mouse anti-CD90/Thy1: FITC (5E10) and Mouse anti- 
CD105: FITC (MEM-229) purchased in Abcam plc (London). The 
following isotype negative control antibodies were used as fluorescence 
minus one controls: Mouse IgG1 (FITC) - Isotype Control, Mouse IgG1 
Negative Control: FITC, Rat IgG1 Negative Control: FITC, Mouse IgG1 
Negative Control: FITC, Mouse IgG2a, kappa monoclonal - Isotype 
Control: FITC and Mouse IgG2b Negative Control: FITC (Bio-Rad, United 
States). DAPI (3.3 µM) was added before analysis to exclude dead cells. 
At least 106 cells were analyzed using a MacQuant Analyzer 10. Un-
stained cells were used to evaluate autofluorescence. In all cytometry 
experiments, at least three samples were analyzed for each condition. 
Flow cytometry analysis was performed by FlowJo software, version 
8.8.7 (TreeStar, Ashland, OR). 
2.7. Molecular characterization of cardiosphere-derived cells by RT-PCR 
The expression of the following markers was analyzed by RT-PCR: 
Kit, Nanog, Mef2c, Gata4, Cx43, Tnni3, Actc1, Vegf-a, Igf-1. Igf-1r, Hgfl, 
Fgfr2 and Tgf-ß1. Cells were de-encapsulated by incubating with 1 mg/ 
mL alginate lyase (Sigma Aldrich, United States) for 30 min at 37 ◦C. The 
lysates were spun down and rinsed twice with DPBS. After complete lysis 
of microcapsules, microcapsules pellets and non-encapsulated cells were 
resuspended in RLT buffer from the RNeasy Mini Kit (Qiagen, Germany). 
RNA was extracted following the manufacturer recommendations. Total 
extracted mRNA was quantified with a SimpliNano nanodrop (GE 
Healthcare Life Sciences, Iceland). cDNA synthesis was performed using 
Fast Gene Scriptase II, cDNA Synthesis Kit (Genetics, Nippon, Europe), 
following PCR amplification with the KAPA2G Robust PCR kit (Sigma 
Aldrich, United States) in a T100 Thermal Cycler (Bio-Rad, United 
States). Amplicons were run in 1.5% agarose gels in parallel to a 2-log 
ladder 1 kb Plus DNA Ladder (New England BioLabs), confirming their 
expected size. Beta-actin (Actb) was used as housekeeping gene. Gene 
expression was quantified by measuring the brightness intensity of each 
band with Bio-Rad-Image-Lab-Software-5.2.1, normalizing to house-
keeping gene expression. At least three independent experiments were 
performed for each gene and condition. 
2.8. Adipogenic, chondrogenic and osteogenic differentiation of porcine 
CDCs 
To induce adipogenic and osteogenic differentiation 1x105 cells/mL 
were seeded into a 6-well-plate. For osteogenic differentiation growth 
CDCs medium was supplemented with 100 nM dexamethasone, 20 mM 
ß-glycerolphosphate and 50 μM L-ascorbic acid. Adipogenic differenti-
ation was induced culturing with growth CDCs medium supplemented 
with 0.5 μM dexamethasone, 0.5 μM 3-isobutyl-1-methylxanthine, and 
50 μM of indomethacin. To induce chondrogenic differentiation, 
2.5x105 cells/mL were seeded in 15 mL conical tubes (Falcone) with 0.5 
mL of growth CDCs medium supplemented with 10 ng/mL TGF-ß 
(Peprotech Inc.), 50 nM L-ascorbic acid and 6.25 μg/mL bovine insulin. 
Each differentiation medium was replaced every 2–3 days for 21 days. 
Cells were maintained at 37 ◦C in humidified 5% CO2 atmosphere. For 
all the differentiation conditions the corresponding control, corre-
sponded to CDCs growth in medium without supplements. For staining, 
after 21 days, non-encapsulated and encapsulated cells were washed 
twice with PBS and DPBS respectively, fixed with formaldehyde and 
stained with: Alizarin Red S for osteogenic differentiation, Oil Red O for 
adipogenic differentiation, and Alcian Blue 8GX for chondrogenic dif-
ferentiation. Differentiated cells were observed by optical microscopy at 
day 21 and imaged. 
2.9. Growth factors release quantifications 
Supernatants after 24 h of complete medium change from cultures 
that began with a cell seeding density of 2.5x105 CDCs or same density 
of encapsulated CDCs were collected at day 1, 7, 14, 21 and 42, and 
stored at − 80 ◦C until further processing. Porcine cytokines levels of 
MSP, TGF-ß1, IGF-1 and VEGF were quantified by ELISA according to 
manufacturer’s instructions. The recommended absorbance was read 
out on an Infinite M200 TECAN plate reader (TECAN Trading AG, 
Switzerland) at the recommended wavelengths. The concentration of 
each growth factor was calculated from the respective standard curve 
and expressed as pg/mL and ng/mL. At least three independent exper-
iments were performed to collect supernatants and the read out for each 
growth factor was performed three times. 
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2.10. Statistical analysis 
Statistical analysis was performed with IBM SPSS software, version 
13.0. Data were expressed as means ± standard deviation, and differ-
ences were considered significant for comparison of groups using 
ANOVA, Tukey’s Post Hoc Test when p < 0.05. Normality tests were 
performed to confirm a normal distribution. 
3. Results and discussion 
3.1. Long term-encapsulated CDCs metabolic activity and viability. 
We chose to isolate the clonogenic porcine CDCs (Blázquez et al., 
2016) in order to evaluate their regenerative capacity after encapsula-
tion. Previous studies have shown that the percentage area of viable 
myocardium within the infarct from mice treated with CDCs for 20 days 
is higher than control group (Smith et al., 2007). Although CDCs express 
stem and endothelial progenitor cells markers, being capable of self- 
renewal and differentiation in vitro (Messina et al., 2004), their reten-
tion and survival after implantation is very low, and their exogenous 
origin can lead to immune response. Alginate microencapsulation, 
therefore, can represent a good alternative by increasing adherence in 
the tissue and reducing immunological reaction after implantation (Van 
Ramshorst et al., 2011, Paul et al., 2009). We used ultrapure low vis-
cosity and high guluronic, since gels formed from alginate at high purity 
does not induce significant foreign body reaction after animal implan-
tation (Orive et al., 2002, Lee et al., 2009). 
CDCs expanded in a plastic-adherent monolayer cell culture when 
observed under optical microscopy (Fig. 1A). CDCs collected from these 
cultures were encapsulated in alginate-poly-L-lysine microcapsules at 4 
× 106 cell/mL density. The physical appearance and morphology of the 
encapsulated CDCs were assessed under optical microscopy. Encapsu-
lated cells were spherical, with an average diameter of 370 ± 10 µm and 
a smooth homogeneous surface, similar to other cell types encapsulated 
with the same conditions by our group, such as MSCs, myoblasts or fi-
broblasts (Cañibano-Hernández et al., 2019, Saenz Del Burgo et al., 
2018, Ciriza et al., 2018, Ciriza et al., 2017, Ciriza et al., 2015). Meta-
bolic activity of encapsulated cells progressively increased until day 21 
of culture after encapsulation, reaching its maximum at this time point 
(Fig. 1B), similarly to the metabolic activity profile shown by encapsu-
lated MSCs (Ciriza et al., 2018). Longer term culture up to 42 days was 
required to detect a significant metabolic activity decrease (Fig. 2B). 
CDCs, therefore, seem to adapt to the microenvironment provided by 
alginate matrix. 
Metabolic activity profile was confirmed by the analysis of encap-
sulated CDCs viability under fluorescence microscopy after calcein 
ethidium staining during the same time of culture. Most of the encap-
sulated cells were stained with calcein, not showing almost ethidium 
staining, and indicating a lack of cell death during all the time points 
studied (Fig. 1C). We could also determine that the shape and volume of 
the capsules remain stable after 42-day culture period. The long-term 
stability of the capsules and the preservation of their morphology are 
requirements to preserve their biocompatibility, closely related to the 
quality of the biomaterial (Ponce et al., 2006). We consider, therefore, 
that the long term preservation of capsule integrity, their spherical and 
smooth shape without irregularities will prevent undesired host re-
actions in a future clinical application (Orive et al., 2003). 
3.2. Encapsulated CDCs keep the same phenotype than non-encapsulated 
CDCs 
We next proceeded to compare the encapsulated CDCs extracellular 
profile before and after encapsulation, in order to determine if encap-
sulation would modify their phenotype. We assessed the cell marker 
phenotype of encapsulated and non-encapsulated porcine CDCs by flow 
cytometry (Fig. 2), analyzing among others the expression of mesen-
chymal markers such as CD29, CD44, CD90, CD105 and CD117, since 
CDCs phenotype is described as similar to MSCs phenotype (Blázquez 
et al., 2016). Although marker panels for MSCs are rather heteroge-
neous, we also identified the expression of CD73, CD29, or CD44 and the 
lack of expression of CD45, since this profile is considered a criteria for 
expanded MSC in several clinical trials (Rojewski et al., 2008). 
Fig. 1. Cell morphology and expansion, metabolic activity and cell viability. (A) CDCs morphology in monolayer cell culture. Scale bar: 50 µm. (B) Metabolic activity 
of the encapsulated CDCs throughout the 42-day period. Values represent mean ± SD. (C) Live-Dead assay (staining with calcein-ethidium) during 42-day period, 
cells stained in red are dead cells and the stained in green are living cells. Scale bar: 100 µm. 
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Thus, encapsulated CDCs, similarly to non-encapsulated CDCs, 
expressed CD29 and CD90 (Fig. 2). CD29 (ß1 integrin), expressed by 
adipocyte progenitors (Rodeheffer et al., 2008) and human epidermal 
stem cells (Jones and Watt, 1993), is observed in combination with other 
cluster of differentiation markers for the identification of MSCs, such as 
CD90, also known as thymocyte antigen 1, commonly associated with 
osteoprogenitor cells (Chung et al., 2013). Encapsulated CDCs kept 
expression of CD44, involved in the interaction between stem cells and 
the niche for stemness maintenance (Wagner et al., 2008), commonly 
used as marker of MSCs in combination with other markers, such as 
CD29 (Rojewski et al., 2008). A small increment of CD105 expression 
was detected in encapsulated CDCs compared to non-encapsulated 
CDCs. Differences in expression of CD105 has also been reported when 
comparing MSCs from different sources, with high expression in bone 
marrow derived MSCs and lower in amnion membrane-derived MSCs 
(Rojewski et al., 2008). We consider that the interaction with alginate 
could activate the expression of CD105. The expression of CD117, 
known as cKit, was also increased in encapsulated CDCs. The expression 
of CD117 in MSCs is controversial since some authors have described 
that MSCs derived from bone marrow do not express CD117 (Jones 
et al., 2002), while other have shown an expression in 50% of the MSC 
population (Titorencu et al., 2007). Other authors have also described 
the expression of CD117 in MSCs in gelatin-alginate hydrogels (Joddar 
et al., 2018), and it could suggest that alginate activate the expression of 
the stemness related marker CD117. 
As expected, a lack of the hematopoietic marker CD45 expression 
was shown by CDCs, either encapsulated or non-encapsulated, accom-
plishing with the criteria stablished by the International Society for 
Fig. 2. Phenotype characterization of encapsulated and non-encapsulated CDCs. Dark and light histograms show isotype control and specific antibody stained sample 
respectively. Values represent mean ± SD for the positive stained cell population. (A) Phenotype characterization of non-encapsulated cells. (B) Phenotype char-
acterization of encapsulated cells. 
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Cellular Therapy, ISCT (Dominici et al., 2006). Similarly, no expression 
of platelet endothelial cell adhesion molecule (PECAM-1 or CD31) was 
observed in CDCs, either encapsulated or non-encapsulated. In contrast, 
CDCs expressed CD61, either in non-encapsulated or encapsulated 
CDCs, as previously reported for MSCs (Duggal et al., 2009). Finally, 
swine leukocyte antigens (SLA), SLA I and SLA II, the homologs to the 
human leukocyte antigens (HLA) HLAI and HLA II respectively, were 
also assessed (Ladowski et al., 2018). Non-encapsulated CDCs expressed 
SLA I but not SLA II (Fig. 2), with similar pattern in encapsulated CDCs, 
accomplishing with ISCT criteria (Dominici et al., 2006). Although mi-
crocapsules can evade immune cells after implantation based on the 
restriction of the diffusion of immune mediators through the pores of the 
microcapsule (Ashimova et al., 2019), the lack of SLAII expression, in 
combination with encapsulation, can lead to circumvent the rejection 
after transplantation of encapsulated CDCs (Essler et al., 2013), avoiding 
the presentation of non-self-antigens by HLA and, therefore, the acti-
vation of CD4+ cells (Zakrzewski et al., 2014). 
3.3. Cdcs resemble MSCs differentiation with higher potential to 
differentiate into osteocytes after cell encapsulation. 
Another criterion to define human MSC is its ability to differentiate 
to osteoblasts, adipocytes and chondrocytes in vitro according to ISCT 
(Dominici et al., 2006). Therefore, we characterized the differentiation 
potential of CDCs into osteoblasts, adipocytes and chondrocytes before 
and after cell encapsulation. After 21 days of differentiation, the pres-
ence of a calcified extracellular matrix in the samples confirmed the 
potential of CDCs to be differentiated into osteocytes (Fig. 3A). More 
intense staining was detected in differentiated encapsulated CDCs 
(Fig. 3B), compared to non-encapsulated CDCs, indicating an enhance-
ment in the potential of differentiation into osteocytes. This differenti-
ation potential increment could be related to the lack of three- 
dimensional architecture of natural tissues in non-encapsulated CDCs 
(two-dimensional culture). Two-dimensional cultures could lead to the 
deterioration of MSCs’ progenitor properties (Fehrer and Lepperdinger, 
2005), while encapsulation would improve osteogenic differentiation of 
the CDC (Bae et al., 2017). 
No differences were detected 21 days after differentiation into adi-
pocytes, with presence of fat vacuoles in encapsulated and non- 
encapsulated CDCs, indicating their ability to differentiate to adipose 
tissue (Fig. 3A), without differences when encapsulated CDCs were 
differentiated (Fig. 3B). When differentiation into chondrocytes was 
assessed after 21 days, sulfated proteoglycan deposits were observed in 
either non-encapsulated and encapsulated CDCs (Fig. 3A-B). Consid-
ering the described potential of encapsulated CDCs, we were able to 
confirm the mesenchymal potential differentiation maintenance in CDCs 
after encapsulation, with an enhancement of differentiation into osteo-
cytes after encapsulation. 
3.4. Cardiac progenitor gene expression of CDCs is maintained after 
encapsulation 
We next quantified the RNA expression from encapsulated and non- 
encapsulated CDCs of several markers related to stemness, early cardiac 
differentiation and mature cardiomyocytes, as well as the expression of 
several growth factors and their receptors, since they represent specific 
roles in cardiac regeneration after myocardial infarction. To analyze the 
expression of those markers, total RNA from encapsulated and not 
encapsulated CDCs was isolated, and RT-PCR analysis performed 
(Fig. 4). The results showed a positive expression of the stemness related 
genes markers (Kit, Nanog), early cardiac differentiation related genes 
markers (Mef2c and Gata-4), mature cardiomyocytes related genes 
markers (Cx43, Tnni3 and Actc1), as well as different growth factors and 
their receptors (Vegf-A, Igf-1, Igf-1r, Hgfl, Fgfr2 and Tfg-ß1). 
Significant differences (p < 0.05) were observed between encapsu-
lated and non-encapsulated CDCs Kit expression (Fig. 4), with an 
increment of expression after encapsulation of CDCs. This increment of 
Kit expression is correlated with data observed by flow cytometry, 
showing CD117+ encapsulated CDCs and CD117low in non-encapsulated 
CDCs (Fig. 2). The glucoprotein CD117 is related to apoptosis regulation, 
Fig. 3. Differentiation of non-encapsulated and encapsulated CDCs with their corresponding controls. (A) Micrographs after 3 weeks of osteogenic, adipogenic and 
chondrogenic non-encapsulated CDCs differentiation. (B) Micrographs after 3 weeks of osteogenic, adipogenic and chondrogenic encapsulated CDCs differentiation. 
Scale bar: 100 µm. 
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cell differentiation, proliferation, chemotaxis, cell adhesion and also 
stemness (Miettinen and Lasota, 2005). In fact, CD117+CD45dim/moderate 
mast cells have been proposed as putative cardiac progenitor cells. We 
believe that the expression of CD117 (Fig. 2) indicate that CDCs could 
differentiate to more mature cardiac progenitors after encapsulation, 
acquiring the phenotype of the aforementioned cardiac progenitor-mast 
cells (Zhou et al., 2010). In contrast, Nanog expression significantly 
decreased after encapsulation (Fig. 4). Nanog is a pluripotency factor 
specifically expressed in stem cells, but rarely in their differentiated 
derivatives. Its expression in stem cells-differentiated derivatives is 
related to form teratomas after transplantation (Rong et al., 2012), 
reducing the appearance of teratomas by inhibiting Nanog (Heaney 
et al., 2012, Rong et al., 2012). The down-regulation of Nanog in 
encapsulated CDCs, therefore, indicates a lower risk in teratoma for-
mation, maybe related with the differentiation of CDCs into more 
mature cardiac progenitors, suggesting a safe clinical transplantation of 
encapsulated CDCs in terms of teratoma formation. 
We did not detect significant differences in the expression of Gata4 
and Mef2c transcription factors when comparing encapsulated and non- 
encapsulated CDCs. Gata4 was highly expressed in both samples, 
corroborating the cardiomyocyte phenotype of CDCs (Fig. 4), since 
Gata4 is highly expressed in cardiomyocytes after a trauma throughout 
the subepicardial ventricular layer (Kikuchi et al., 2010), and fibroblasts 
can be directly reprogrammed to cardiomyocytes by overexpressing a 
combination of the cardiac specific transcription factors Gata4 and 
Mef2c (Tani et al., 2018). When analyzing the expression of Cx43, a 
mature cardiomyocytes related gene marker, significant lower expres-
sion was quantified in encapsulated CDCs (Fig. 4). Cx43 is the major gap 
junction protein expressed in the heart, altered substantially after 
myocardial infarction (Fontes et al., 2012). We consider that the 
reduction of Cx43 expression in encapsulated CDCs reflect the lower 
interaction between cells in the 3D scaffold compared to 2D cultures, not 
indicating a lack of mature cardiac marker. Moreover, Cx43 expression 
enhancement to reduce susceptibility to arrhythmias is still unclear, 
since its reduced expression attenuates ventricular remodeling after 
myocardial infarction via impaired Tgf-β1 signaling (Zhang et al., 2010). 
No significant differences were detected between encapsulated and non- 
encapsulated CDCs when Tnni3 or Actc1 were compared, codifying 
troponin I and actin alpha cardiac muscle 1 respectively. Both are nor-
mally expressed in cardiac muscle, indicating that the cardiac phenotype 
of CDCs is kept after encapsulation. 
The expression of the pro-angiogenic vascular endothelial growth 
factor receptor (Vegf-a), did not show significant differences between 
non-encapsulated and encapsulated CDCs (Fig. 4), indicating that their 
implantation in vivo will lead to an increase in the number of endothelial 
cells and shorter extravascular distances in the infarct zone, improving 
vascularization and oxygen diffusion (Zak et al., 2019). No significant 
differences were also observed in the expression of insulin-like growth 
factor 1 (Igf-1) and insulin-like growth factor 1 receptor (Igf-1r) between 
encapsulated and non-encapsulated CDCs. We also quantified significant 
higher expression of Hgfl in encapsulated CDCs compared to non- 
encapsulated. Since, hepatocyte growth factor-like protein (Hgfl) is a 
potential candidate for boosting migration, engraftment and commit-
ment of resident cardiac stem cells (Madonna et al., 2010), similarly to 
its behavior in liver regeneration (Bezerra et al., 1994), these results 
point out to encapsulated CDCs as a putative tool for cardiac regenera-
tion (Madonna et al., 2012). 
When analyzing the expression of Fgfr2, the fibroblast growth factor 
receptor 2 involved in diverse biological and cellular processes, such as 
cell proliferation, apoptotic resistance, angiogenesis, differentiation and 
tissue regeneration (Katoh and Nakagama, 2014), non-significant higher 
expression was quantified in encapsulated CDCs (Fig. 4). We also did not 
detect a significant difference in the expression of Tgf-ß1, tumour growth 
factor beta 1, comparing encapsulated and non-encapsulated CDCs. 
Overall, we can conclude that cardiac progenitor gene expression of 
CDCs is maintained after encapsulation with slight beneficial modifi-
cations after encapsulation, such as decrease in Nanog or an increment in 
cKit or Hgfl expression. 
3.5. Sustained release of growth factors from encapsulated CDCs 
Next, we quantified the release of growth factors involved in cardiac 
regeneration. We collected supernatants from encapsulated and non- 
encapsulated CDCs during 42-days, quantifying several growth factors. 
Thus, we identified a sustained and gradual release of VEGF, in either 
encapsulated or non-encapsulated CDCs during 42 days without signif-
icant differences. Moreover, no significant differences were identified 
between encapsulated and non-encapsulated CDCs VEGF release (Fig. 5. 
A), indicating that encapsulation does not affect the release of VEGF. 
Since VEGF induce vasculogenesis and angiogenesis, stimulating the 
formation of blood vessels to providing more effective muscle regener-
ation (Frey et al., 2012) and restoring the oxygen supply into tissues 
when blood circulation is inadequate in hypoxic conditions, we can 
conclude that the implantation of encapsulated CDCs into cardiac 
infarcted tissues would promote blood vessels formation and oxygen 
supply, enhancing cardiac tissue regeneration. 
We also quantified TGF-ß1 release from encapsulated and non- 
encapsulated samples for 42 days. A gradual increment in TGF-ß1 
Fig. 4. Gene expression of non-encapsulated and encapsulated CDCs. Data represent the fold regulation between the gene of interest and the housekeeping. Note: 
***: p < 0.001; **: p < 0.01 and *: p < 0.05 comparing non-encapsulated CDC to encapsulated CDC gene expression of each gene. 
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release was quantified in non-encapsulated CDCs, with significant dif-
ferences at day 21 and 42 compared to day 1. In contrast, in encapsu-
lated CDCs, a significant TGF-ß1 release increment was only quantified 
at day 42 of collection. Moreover, a significant lower TGF-ß1 release was 
quantified at each time point when comparing non-encapsulated CDC to 
its encapsulated counterpart (Fig. 5.B). Interestingly, the quantification 
of TGF-ß1 gene expression was non-significantly higher in encapsulated 
CDCs, indicating that there is partial retention of the growth factor in the 
microcapsules that precludes its release. TGF-ß1 release is primordial in 
regeneration after myocardial infarction, since promotes the trans-
formation of cardiac fibroblasts to myofibroblasts, (Tarbit et al., 2019, 
Chen et al., 2016) and regulates the inflammatory and reparative 
response following infarction, with a wide range of actions on vascular 
cells, cardiomyocytes, fibroblasts and immune cells (Hanna and Fran-
gogiannis, 2019, Frangogiannis, 2017). However, TGF-β1 over-
expression in the mouse heart is associated with fibrosis and 
hypertrophy (Rosenkranz et al., 2002, Huntgeburth et al., 2011). 
Therefore, a sustained TGF-β1 release without gradual increment over-
time could result more convenient if CDCs are implanted in cardiac 
infarcted models, pointing out to encapsulated CDCs as a more reliable 
therapy for clinical cardiac regeneration. 
We also quantified a progressive decrease in MSP release overtime in 
either non-encapsulated or encapsulated CDCs, with a slight increment 
at day 42 in encapsulated CDCs (Fig. 5.C). No significant differences 
were identified between non-encapsulated and encapsulated CDCs, 
indicating that encapsulation does affect the MSP release, although a 
slight retention is detected by alginate microcapsules. MSP is a factor 
related to hepatocyte growth factor (Brunelleschi et al., 2001), that 
exerts proliferative and antiapoptotic effects, being upregulated during 
regeneration of injured tubular cells, and exerting biological effects that 
may aid recovery from acute kidney injury (Cantaluppi et al., 2008). In 
the heart, infiltrating macrophages can be primed to acquire a car-
dioprotective phenotype in ischemic heart, exerting a proactive effect 
through activation of an antiapoptotic program in cardiomyocytes 
(Frangogiannis, 2015). Although the release of encapsulated CDCs is 
lower than non-encapsulated CDCs, we envision that the sustained 
released of this factor could exert a protective effect against apoptosis 
after infarction. 
Finally, we quantified IGF-1 release from encapsulated and non- 
encapsulated CDCs. A significant progressive IGF-1 release increment 
overtime was quantified in non-encapsulated CDCs (Fig. 5.D). In 
contrast, encapsulated CDCs showed a sustained IGF-1 release with a 
significant decrease at day 42 after encapsulation, indicating again a 
partial retention of the growth factor in the alginate microcapsules, 
supported by the higher Igf-1 expression quantified in encapsulated 
CDCs (Fig. 4). Transplantation of MSCs secreting IGF-1 after a myocar-
dial infarction significantly increases neovascularization, inhibiting 
apoptosis of cardiomyocytes after third day of transplantation (Enoki 
et al., 2010). Similar to MSP, we consider that, even with a lower IGF-1 
release compared to non-encapsulated CDCs, the sustained release of 
IGF-1 would benefit in cardiac regeneration during the first month of 
transplantation. Overall, we can conclude that the implantation of 
encapsulated CDCs will promote infarcted tissue regeneration, by a 
sustained release of the aforementioned factors, giving rise to the for-
mation of new blood vessels, allowing the maturation of cardiac fibro-
blasts into myofibroblasts, and inhibiting apoptosis. 
4. Conclusions 
We have shown that porcine CDCs encapsulation does not alter CDCs 
features, while maintaining a long viability up to a month. In fact, 
encapsulated CDCs keep the same phenotype than non-encapsulated 
CDCs, with a phenotype similar to MSCs, resembling also MSCs differ-
entiation potential into osteoblasts, adipocytes and chondrocytes, with a 
slight increment in differentiation into osteoblasts. However, our results 
show that encapsulation activates the expression of the stemness related 
marker CD117, correlating the gene expression with the surface protein 
expression. These results, the quantified decrease of Nanog expression 
after encapsulation and a gene expression profile similar to cardiac 
progenitor cells, suggest that encapsulated CDCs are committed cardiac 
progenitor cells, with low risk of teratoma formation if encapsulated 
CDCs would be implanted. Interestingly, we have also quantified a 
sustained release of the growth factors VEGF, TGF-ß1, MSP and IGF-1 
from encapsulated CDCs, suggesting that the implantation of encapsu-
lated CDCs would promote the formation of new blood vessels and the 
regeneration of infarcted cardiac tissue. Altogether, we can conclude 
Fig. 5. Release profile of different growth factors in non-encapsulated and encapsulated CDCs throughout 42-days period. (A) VEGF (pg/mL). (B) TFGß1 (pg/mL). 
(C) MSP (ng/mL). (D) IGF (ng/mL). Note: ***: p < 0.001; **: p < 0.01 and *: p < 0.05. compared to day 1. 
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that encapsulated CDCs represent an alternative in cardiac regenerative 
medicine of myocardial infarction, providing a step forward to their 
clinical translation. 
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Cañibano-Hernández, A., Saenz Del Burgo, L., Espona-Noguera, A., Orive, G., Hernández, 
R.M., Ciriza, J., Pedraz, J.L., 2019. Hyaluronic Acid Promotes Differentiation of 
Mesenchymal Stem Cells from Different Sources toward Pancreatic Progenitors 
within Three-Dimensional Alginate Matrixes. Mol. Pharm. 16, 834–845. https://doi. 
org/10.1021/acs.molpharmaceut.8b01126. 
Cantaluppi, V., Biancone, L., Romanazzi, G.M., Figliolini, F., Beltramo, S., Galimi, F., 
Camboni, M.G., Deriu, E., Conaldi, P., Bottelli, A., Orlandi, V., Herrera, M.B., 
Pacitti, A., Segoloni, G.P., Camussi, G., 2008. Macrophage stimulating protein may 
promote tubular regeneration after acute injury. J. Am. Soc. Nephrol. 19, 
1904–1918. https://doi.org/10.1681/ASN.2007111209. 
Chen, C., Li, R., Ross, R.S., Manso, A.M., 2016. Integrins and integrin-related proteins in 
cardiac fibrosis. J. Mol. Cell. Cardiol. https://doi.org/10.1016/j.yjmcc.2015.11.010. 
Chiu, R.C.J., 2003. Adult stem cell therapy for heart failure. Expert Opin. Biol. Ther. 
https://doi.org/10.1517/14712598.3.2.215. 
Chung, M.T., Liu, C., Hyun, J.S., Lo, D.D., Montoro, D.T., Hasegawa, M., Li, S., Sorkin, 
M., Rennert, R., Keeney, M., Yang, F., Quarto, N., Longaker, M.T., Wan, D.C., 2013. 
CD90 (Thy-1)-positive selection enhances osteogenic capacity of human adipose- 
derived stromal cells. Tissue Eng. - Part A 19, 989–997. https://doi.org/10.1089/ 
ten.tea.2012.0370. 
Ciriza, J., Del Burgo, L.S., Gurruchaga, H., Borras, F.E., Franquesa, M., Orive, G., 
Hernández, R.M., Pedraz, J.L., 2018. Graphene oxide enhances alginate 
encapsulated cells viability and functionality while not affecting the foreign body 
response. Drug Deliv. 25, 1147–1160. https://doi.org/10.1080/ 
10717544.2018.1474966. 
Ciriza, J., del Burgo, L.S., Hernández, R.M., Orive, G., Pedraz, J.L., 2017. Use of flow 
focusing technique for microencapsulation of myoblasts. In: Methods in Molecular 
Biology. Humana Press Inc., pp. 207–216. https://doi.org/10.1007/978-1-4939- 
6364-5_16 
Ciriza, J., Saenz Del Burgo, L., Virumbrales-Muñoz, M., Ochoa, I., Fernandez, L.J., 
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